ClinicalTrials.gg
CompletedNCT03565107Updated Nov 4, 2024

Characterization of Methylation Pattern in Human Germ Cells of Patients Undergoing ICSI Treatment

An observational study in Female Infertility and Gene Deregulation, sponsored by Infertility Treatment Center Dortmund. Completed at 1 site in Germany. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-04.

Sponsored by Infertility Treatment Center Dortmund · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
156
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Infertility, Female with a site in Germany — none open to participants now, 2 under way, none of them phase 3. Infertility, Female · Germany.

Started
2018
with 1 other
Observational
7 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
4 of 12
Infertility Treatment Center Dortmund

Among the 12 studies in Infertility, Female with a site in Germany, this one is one of 2 that started in 2018, is one of 7 observational ones, and was the 7th registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

None of the 12 studies in Infertility, Female with a site in Germany is open now. The open studies under Infertility, Female, anywhere →

Who these studies take

Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Infertility, Female with a site in Germany as a file.
02

Study summary

There is increasing evidence that exposure to environmental factors in early development is associated with an increased risk of metabolic and other common diseases. These increased disease risks are likely due to environmental-induced epigenetic changes leading to dysregulation of genes and signaling cascades. The best studied epigenetic modification in this context is DNA methylation. Preliminary studies have already shown that an increased father age or intracytoplasmic sperm injection affects methylation pattern in sperm or umbilical cord blood of children. Unlike sperm, less is known about the methylation of human oocytes and their susceptibility to environmental factors. The aim of this study is to analyze the methylation pattern of immature oocytes of women with decreased fertility. Based on the results of a large number of oocytes from different women, risk assessments could be made for individual factors such as the age of the patient, as well as correlations between the occurrence of changes in gene expression and the unfulfilled desire to have children. In addition, the methylation patterns in sperm from 20 patients are to be examined as reference patterns.

Read the detailed description

Although more than five million children have been conceived worldwide through Assisted Reproduction Techniques (ARTs), little is known about potential effects of ART in later life. So far, the focus of reproductive research is based on the success rate of infertility treatment. There is increasing evidence that exposure to environmental substances, age of the patient or in vitro culture conditions in early development is associated with a life-long increased risk of metabolic and other common diseases. These increased disease risks are likely due to environmental-induced epigenetic changes leading to dysregulation of genes and signaling cascades. These include Beckwith-Wiedemann and Angelman syndrome.

The best studied epigenetic modification in this context is DNA methylation, which regulates the gene expression in a temporally and highly coordinated manner. Preliminary studies have already shown that an increased father age influences the pattern of methylation in the sperm and umbilical cord blood of children. Moreover, intracytoplasmic sperm injection (ICSI) also leaves epigenetic signatures in umbilical cord blood. Unlike sperm, little is known about the methylation of human oocytes and their susceptibility to environmental factors. The main reason for this is the difficulty of collecting human oocytes in sufficient numbers for genome-wide analysis. The aim of this study is to analyze the methylation pattern of immature oocytes, which are not suitable for further ICSI treatment, of women with decreased fertility. The products of gene expression and also the methylation of the DNA itself can be investigated using newly developed DNA sequencing methods. Based on the results of a large number of oocytes from different women, risk assessments could be made for individual factors such as the age of the patient, as well as correlations between the occurrence of changes in gene expression and the unfulfilled desire to have children. In addition, the methylation patterns in sperms from 20 patients are to be examined as reference.

03

Conditions studied

  • Female Infertility
  • Gene Deregulation

Browse trials for

Keywords

  • Epigenetic
  • Female age
  • Gene regulation
  • Methylation pattern
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

female patients seeking ICSI treatment because of male subfertility

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy females without sterility factors

Exclusion criteria

Exclusion Criteria:

  • Endometriosis
  • Polycystic ovary syndrome (PCO)
  • Neoplasia (ovary, Uterus, breast)
  • Anti-Müllerian hormone (AMH) \<1 ng/ml
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
156 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Female Patients

    ICSI treatment because of male subfertility

06

What researchers measure

Primary outcomes

  1. Methylation pattern

    Analysis of methylation pattern in immature oocytes (not suitable for further ICSI treatment). Methylation will be pointed out as number of methylated gene loci in comparison to the overall amount of analyzed gene loci.

    Time frame: 1 day (Directly after oocyte pick-up)

  2. Gene expression

    Analysis of gene expression in immature oocytes (not suitable for further ICSI treatment) will be done by quantification of selected gene transcripts (in picogram).

    Time frame: 1 day (Directly after oocyte pick-up)

07

Study locations

1 site
  • Infertility treatment center Dortmund
    Dortmund, NRW 44135, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jul 2024, 72 months.

Of 85 non-industry observational studies under Infertility, Female, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 69. This study's 72 months is above that.

Counting every sponsor, half of 88 studies reached it within 36 months; a quarter within 18 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2018
First posted
Jun 21, 2018
StartActual
Jul 1, 2018
Primary completionActual
Jul 17, 2024
CompletionActual
Oct 31, 2024
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03565107
Lead sponsor
Infertility Treatment Center Dortmund
Collaborators
University of Wuerzburg
Responsible party
Sponsor
First posted
Jun 21, 2018
Start date
Jul 1, 2018
Primary completion
Jul 17, 2024
Completion
Oct 31, 2024
Last update
Nov 4, 2024

Study contacts

Stefan Dieterle, MD
principal investigator · Infertility Treatment Center Dortmund

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion